Moneycontrol PRO
HomeNewsInspection

Inspection

Jump to
  • KFin Tech settles case with Sebi for Rs 87.75 Lakh

    KFin Tech settles case with Sebi for Rs 87.75 Lakh

    Sebi's inspection report alleged that the company failed to exercise due diligence while processing requests for dematerialisation of shares

  • Sebi cracked down on 89 market manipulators in FY25 through surveillance and analytics

    Sebi cracked down on 89 market manipulators in FY25 through surveillance and analytics

    Sebi said it has added multiple new data sources and new analytics tools that have significantly streamlined analysis, reduced time and manual effort, thus improving accuracy in identifying violators.

  • US FDA makes observation on Lupin's Aurangabad plant

    US FDA makes observation on Lupin's Aurangabad plant

    The FDA inspected the Aurangabad facility between March 6 and 15

  • Regulator begins major enforcement drive on poor drug-making practices

    Regulator begins major enforcement drive on poor drug-making practices

    These enforcement actions are a part of risk-based inspection to ensure Good Manufacturing Practices (GMP) norms are met

  • Cipla's Pithampur unit gets 8 observations from USFDA after inspection

    Cipla's Pithampur unit gets 8 observations from USFDA after inspection

    The US Food and Drug Administration (USFDA) conducted a current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility from February 6 - 17

  • Zuari Agro Chemical under MCA lens over corporate governance violations

    Zuari Agro Chemical under MCA lens over corporate governance violations

    The Ministry of Corporate Affairs' western regional director office has ordered an inspection under Section 206 of the Company's Act.

  • To cut healthcare costs, US must partner India: Biocon's Shaw

    To cut healthcare costs, US must partner India: Biocon's Shaw

    Biocon Chief Kiran Mazumdar Shaw says India is not an outsourced services country anymore, it is an innovation and knowledge partner.

  • Allow inspection of Smriti Irani's board record: CIC to CBSE

    Allow inspection of Smriti Irani's board record: CIC to CBSE

    The Central Information Commission today directed the Central Board of Secondary Examination to allow inspection of class 10th and 12th school records of Union Minister Smriti Irani, rejecting CBSE's contention that it constituted "personal information".

  • Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal

    Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal

    USFDA has issued notice to the Hyderabad unit of Aurobindo Pharma and calming the nerves of the investors Surajit Pal of Prabhudas Lilladher says that it is a non-event and there is no need to worry.

  • Caplin Point Labs Chennai plant to be inspected by FDA in Oct

    Caplin Point Labs Chennai plant to be inspected by FDA in Oct

    Drug firm Caplin Point Laboratories today said US health regulator would conduct a prior approval inspection of its Gummidopoondi facility in Chennai in October.

  • USFDA completes inspection of Alkem's Taloja plant; shares up 2%

    USFDA completes inspection of Alkem's Taloja plant; shares up 2%

    United States Food and Drug Administration (USFDA) has successfully completed the inspection of company's bioequivalence facility located at Taloja, Maharashtra.

  • USFDA finds minor violations at Lupin's Dabhasa plant

    USFDA finds minor violations at Lupin's Dabhasa plant

    Drug firm Lupin on July 8 said US health regulator has voiced minor concerns after completing the inspection of its Dabhasa facility in Gujarat

  • Maggi exceeded lead content, violated labelling rules: Govt

    Maggi exceeded lead content, violated labelling rules: Govt

    Samples of Nestle's Maggi noodles were found to be containing more than the permissible limit of 2.5 ppm of lead and also violating the labelling requirements about presence of Monosodium Glutamate (MSG).

  • NSEL probe gathers momentum; EOW questions former CFO: Srcs

    NSEL probe gathers momentum; EOW questions former CFO: Srcs

    The probe into the beleaguered National Spot Exchange has gathered momentum as the economic offences wing is investigating multiple angles into the scam.

  • Wockhardt's Aug USFDA check vital for stock revival: IIFL

    Wockhardt's Aug USFDA check vital for stock revival: IIFL

    Bino Pathiparampil, vice president-research, IIFL views come on a day when the stock has tanked 20 percent on the back of the USFDA‘s warnings over the pharma major‘s manufacturing practices.

  • Wockhardt plunges after Macquarie downgrades to 'neutral'

    Wockhardt plunges after Macquarie downgrades to 'neutral'

    While the stock valuations still remain supportive, multiples could be under pressure in the near to medium-term, driven by uncertainty around remediation timelines and future approvals, Macquarie says.

  • Citi maintains 'buy' on Wockhardt, target Rs 2,500

    Citi maintains 'buy' on Wockhardt, target Rs 2,500

    Citigroup Global Markets maintained its "buy" rating on pharma major Wockhardt, saying recent plant inspection and subsequent observations raised by US Food and Drug Administration wouldn't have any immediate impact on the co's business.

  • Wockardt slumps on US FDA plant inspection

    Wockardt slumps on US FDA plant inspection

    Pharma major Wockhardt slumped 10 percent on Friday on reports that the US Food and Drugs Administration had issued a 483 form through a routine course of inspection of one of its plants. The inspection was for its injectables facility in Aurangabad.

  • MCA inspection finds no a/c faults at DLF; stock up

    MCA inspection finds no a/c faults at DLF; stock up

    MCA inspection found no account faults at DLF. MCA‘s regional director reported only 2 'technical faults', reports CNBC-TV18.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347